Case: 15-2066 Document: 139 Page: 1 Filed: 08/09/2017
`
`Nos. 2015-2066, 2016-1008, -1009, -1010, -1109, -1110, -1283, -1762
`
`
`
`In the United States Court of Appeals for the Federal Circuit
`__________
`
`MILLENNIUM PHARMACEUTICALS, INC.,
`PLAINTIFF-APPELLANT,
`
`v.
`
`SANDOZ INC., ACCORD HEALTHCARE INC., ACTAVIS LLC, MYLAN LABORATORIES
`LIMITED, AGILA SPECIALTIES INC., DR. REDDY’S LABORATORIES, LTD., DR. REDDY’S
`LABORATORIES, INC., SUN PHARMACEUTICAL INDUSTRIES, LIMITED, SUN PHARMA
`GLOBAL FZE, APOTEX CORP., APOTEX INC., TEVA PHARMACEUTICALS USA, INC.,
`GLENMARK PHARMACEUTICALS LTD., GLENMARK GENERICS LTD., GLENMARK
`GENERICS INC., USA, HOSPIRA, INC., WOCKHARDT BIO AG, WOCKHARDT USA LLC,
`DEFENDANTS-APPELLEES
`__________
`Appeals from the United States District Court for the District of Delaware
`in Nos. 1:12-cv-01011-GMS, 1:12-cv-01490-GMS, 1:12-cv-01750-GMS, 1:13-cv-01874-
`GMS, 1:14-cv-01156-GMS, 1:15-cv-00040-GMS, 1:15-cv-00539-GMS, 1:15-cv-00540-
`GMS, 1:15-cv-00804-GMS, and 1:16-cv-00034-GMS, Judge Gregory M. Sleet.
`__________
`DEFENDANTS-APPELLEES’ SANDOZ INC., ACCORD HEALTHCARE
`INC., ACTAVIS LLC, MYLAN LABORATORIES LIMITED, AGILA
`SPECIALTIES INC., DR. REDDY’S LABORATORIES, LTD., DR. REDDY’S
`LABORATORIES, INC., GLENMARK PHARMACEUTICALS LTD.,
`GLENMARK GENERICS LTD., GLENMARK GENERICS INC., USA,
`HOSPIRA, INC., SUN PHARMACEUTICAL INDUSTRIES, LIMITED, SUN
`PHARMA GLOBAL FZE’S AND WOCKHARDT BIO AG AND
`WOCKHARDT USA LLC’S UNOPPOSED MOTION FOR EXTENSION OF
`TIME TO PETITION FOR REHEARING
`__________
`
`ROBYN AST-GMOSER
`POLSINELLI PC
`100 S. Fourth Street, Suite 1000
`St. Louis, MO 63102
`(314) 622-6614
`rastgmoser@polsinelli.com
`Counsel for Petitioner Actavis LLC
`
`STEFFEN N. JOHNSON
`ANDREW C. NICHOLS
`Winston & Strawn LLP
`1700 K Street, N.W.
`Washington, DC 20006
`(202) 282-5000
`sjohnson@winston.com
`anichols@winston.com
`Counsel for Petitioner Sandoz Inc.
`
`Counsel Continued on Next Page
`
`

`

`Case: 15-2066 Document: 139 Page: 2 Filed: 08/09/2017
`
`Counsel continued
`
`
`
`
`
`GEORGE C. LOMBARDI
`MAUREEN L. RURKA
`KATHLEEN B. BARRY
`WINSTON & STRAWN LLP
`35 W. WACKER DRIVE
`CHICAGO, IL 60601
`(312) 558-5600
`mrurka@winston.com
`kbarry@winston.com
`Counsel for Sandoz Inc.
`
`
`PAUL A. BRAIER
`P. BRANKO PEJIC
`GREENBLUM & BERNSTEIN, P.L.C.
`1950 Roland Clarke Place
`Reston, VA 20191
`(703) 716-1191
`pbraier@gbpatent.com
`bpejic@gbpatent.com
`Counsel for Petitioner
`Accord Healthcare Inc.
`
`
`STUART D. SENDER
`LOUIS H. WEINSTEIN
`ELLEN T. LOWENTHAL
`BUDD LARNER, P.C.
`150 John F. Kennedy Parkway
`Short Hills, NJ 07078
`(973) 379-4800
`ssender@buddlarner.com
`lweinstein@buddlarner.com
`elowenthal@buddlarner.com
`Counsel for Petitioners
`Dr. Reddy’s Laboratories, Ltd. and
`Dr. Reddy’s Laboratories, Inc.
`Counsel Continued on Next Page
`
`GARY E. HOOD
`MARK T. DEMING
`KHURRAM NAIK
`POLSINELLI PC
`150 North Riverside Plaza, Suite 3000
`Chicago, IL 60606
`(312) 819-1900
`ghood@polsinelli.com
`mdeming@polsinelli.com
`knaik@polsinelli.com
`Counsel for Petitioner Actavis LLC
`
`TUNG-ON KONG
`WILSON SONSINI GOODRICH
`& ROSATI P.C.
`One Market Street
`Spear Tower, Suite 3600
`San Francisco, CA 94105
`(415) 947-2000
`tkong@wsgr.com
`Counsel for Petitioners
`Mylan Laboratories Limited
`and Agila Specialties Inc.
`
`ELHAM F. STEINER
`WILSON, SONSINI, GOODRICH
`& ROSATI, PC
`12235 El Camino Real, Suite 200
`San Diego, CA 92130
`(858) 350-2300
`esteiner@wsgr.com
`Counsel for Petitioners
`Mylan Laboratories Limited
`and Agila Specialties Inc.
`
`
`
`53097100.2
`
`2
`
`

`

`Case: 15-2066 Document: 139 Page: 3 Filed: 08/09/2017
`
`
`
`Counsel Continued
`
`CHRISTOPHER J. SORENSON
`RACHEL C. HUGHEY
`AARON M. JOHNSON
`MERCHANT & GOULD
`IDS Center 3200
`80 South Street
`Minneapolis, MN 55402
`(612) 332-5300
`csorenson@merchantgould.com
`rhughey@merchantgould.com
`ajohnson@merchantgould.com
`Counsel for Petitioners
`Sun Pharmaceutical Industries Lim-
`ited and Sun Pharma Global FZE
`
`THOMAS J. MELORO
`MICHAEL W. JOHNSON
`WILLKIE FARR & GALLAGHER LLP
`787 Seventh Avenue
`New York, NY 10019
`(212) 728-8000
`tmeloro@willkie.com
`mjohnson1@willkie.com
`Counsel for Petitioner Hospira, Inc.
`
`
`
`JAY P. LESSLER
`PAUL M. ZAGAR
`BLANK ROME LLP
`405 Lexington Avenue
`New York, NY 10174
`(212) 885-5176
`jlessler@blankrome.com
`pzagar@blankrome.com
`Counsel for Petitioners
`Glenmark Pharmaceuticals Ltd.,
`Glenmark Generics Ltd., and
`Glenmark Generics Inc., USA
`
`
`PATRICK GALLAGHER
`DUANE MORRIS LLP
`190 South LaSalle Street
`Chicago, IL 60603
`(312) 499-6700
`pcgallagher@duanemorris.com
`Counsel for Petitioners
`Wockhardt Bio AG and
`Wockhardt USA LLC
`
`
`
`
`
`53097100.2
`
`3
`
`

`

`
`
`
`
`
`
`Case: 15-2066 Document: 139 Page: 4 Filed: 08/09/2017
`
`CERTIFICATE OF INTEREST
`Counsel for Petitioner Accord Healthcare, Inc. certifies the following:
`
`1.
`
`The full name of every party or amicus represented by me is:
`
`The name of the real party in interest represented by me is:
`
`Accord Healthcare, Inc.
`
`2.
`
`N/A
`
`All parent corporations and any publicly held companies that own 10
`3.
`percent or more of the stock of the party or amicus curiae represented by me are:
`
`Intas Pharmaceuticals Ltd.
`
`The names of the law firms and the partners or associates that appeared
`4.
`for the party or amicus now represented by me in the trial court or agency or are
`expected to appear in this court are:
`
`Greenblum & Bernstein, P.L.C. – Paul A. Braier, P. Branko Pejic, Neil F.
`Greenblum, Michael J. Fink, Jill M. Browning, and Jeffrey Handelsman
`Young Conaway Stargatt & Taylor, LLP – Adam W. Poff and Monté T.
`Squire
`
`
`
`Dated: August 9, 2017
`
`By: /s/Paul A. Braier
`Paul A. Braier
`Greenblum & Bernstein
`1950 Roland Clarke Place
`Reston, VA 20191
`Tel.: (703) 716-1191
`Attorneys for Petitioner
`Accord Healthcare, Inc.
`
`1
`
`

`

`Case: 15-2066 Document: 139 Page: 5 Filed: 08/09/2017
`
`
`
`CERTIFICATE OF INTEREST
`Counsel for Petitioner Actavis LLC certifies the following:
`
`1.
`
`The full name of every party or amicus represented by me is:
`
`Actavis LLC
`
`2.
`
`The name of the real party in interest represented by me is:
`
`N/A
`
`All parent corporations and any publicly held companies that own 10
`3.
`percent or more of the stock of the party or amicus curiae represented by me are:
`
`Allergan plc
`
`The names of the law firms and the partners or associates that appeared
`4.
`for the party or amicus now represented by me in the trial court or agency or are
`expected to appear in this court are:
`
`Polsinelli PC - Gary E. Hood, Pamela Avallone (formerly Fekete), Robyn Ast-
`Gmoser, Mark T. Deming, Khurram Naik, and Christine M. Cochran; Richards Lay-
`ton & Finger - Steven J. Fineman and Jason J. Rawnsley; Duane Morris LLP - Matt
`Neiderman, Anthony J. Fitzpatrick, Vincent L. Capuano, and Laura A. Vogel.
`
`
`
`Dated: August 9, 2017
`
`
`
`By: /s/Robyn Ast-Gmoser
`Robyn Ast-Gmoser
`Polsinelli PC
`100 S. Fourth Street, Suite 1000
`St. Louis, MO 63102
`Tel: (314) 622-6614
`Attorneys for Petitioner
`Actavis LLC
`
`2
`
`

`

`Case: 15-2066 Document: 139 Page: 6 Filed: 08/09/2017
`
`
`
`CERTIFICATE OF INTEREST
`
`Counsel for Petitioners Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s La-
`boratories, Inc. certifies the following:
`
`
`
`1.
`
`The full name of every party or amicus represented by me is:
`
` Dr. Reddy’s Laboratories, Ltd.; Dr. Reddy’s Laboratories, Inc.
`
`
`
`The name of the real party in interest (Please only include any real party
`2.
`in interest NOT identified in Question 3. below) represented by me is:
` N/A
`
`3. All parent corporations and any publicly held companies that own 10
`percent of the stock of the party or amicus curiae represented by me are listed below.
`(Please list each party or amicus curiae represented with the parent or publicly held
`company that owns 10 percent or more so they are distinguished separately.)
` Dr. Reddy’s Laboratories, Inc. is wholly owned by Dr. Reddy’s Laboratories,
` Ltd. No publicly held company owns 10 percent or more of the stock of Dr.
` Reddy’s Laboratories, Ltd.
`
`The names of all law firms and the partners or associates that appeared
`4.
`
`for the party or amicus now represented by me in the trial court or agency or are
`expected to appear in this court are:
` Budd Larner, P.C.: Louis H. Weinstein, Stuart D. Sender, Ellen T. Lowenthal
` Philips, Goldman & Spence, P.A.: John C. Philips, Jr., David A. Bilson
`
`Dated: August 9, 2017
`
`By: /s/ Stuart D. Sender
`Stuart D. Sender
`Budd Larner, P.C.
`150 John F. Kennedy Parkway
`Short Hills, NJ 07078
`Tel.: (973) 379-4800
`Attorneys for Petitioners
`Dr. Reddy’s Laboratories, Ltd. and
`Dr. Reddy’s Laboratories, Inc.
`
`3
`
`

`

`Case: 15-2066 Document: 139 Page: 7 Filed: 08/09/2017
`
`
`
`CERTIFICATE OF INTEREST
`
`Counsel for Petitioners Glenmark Pharmaceuticals Ltd., Glenmark Generics Ltd.,
`and Glenmark Generics Inc., USA certify the following:
`
`
`
`1.
`
`The full name of every party or amicus curiae represented by me is:
`
` Glenmark Pharmaceuticals Ltd., Glenmark Generics Ltd., and Glenmark Generics
`Inc., USA.
`
`The name of the real party in interest (if the party named in the caption
`2.
`
`is not the real party in interest) represented by me is:
`
`Glenmark Generics Inc., USA has changed its name to Glenmark Pharmaceu-
`
`ticals Inc., USA, which is wholly owned by Glenmark Pharmaceuticals Ltd.
`
`Glenmark Generics Ltd. has merged into Glenmark Pharmaceuticals Ltd.
`
`All parent corporations and any publicly held companies that own 10
`3.
`
`percent or more of the stock of the party or amicus curiae represented by me are:
`
`(a) Glenmark Generics Inc., USA (now known as Glenmark Pharmaceuticals
`Inc., USA) is wholly owned by Glenmark Pharmaceuticals Ltd.
`
`(b) Glenmark Generics Ltd. has merged into Glenmark Pharmaceuticals Ltd.,
`a corporation duly formed and publicly traded under the laws of India.
`
` (c) Glenmark Pharmaceuticals Ltd. has no parent company, and no publicly
`traded company owns 10% or more of Glenmark Pharmaceuticals Ltd.
`
`The names of all law firms and the partners or associates that appeared
`4.
`
`for the party or amicus now represented by me in the trial court or agency or are
`expected to appear in this court are:
`
`
`
`
`
`
`
`Jay P. Lessler
`Paul M. Zagar
`BLANK ROME LLP
`
`
`
`4
`
`

`

`Case: 15-2066 Document: 139 Page: 8 Filed: 08/09/2017
`
`
`
`Dated: August 9, 2017
`
`
`
`By: /s/ Paul M. Zagar
`Paul M. Zagar
`BLANK ROME LLP
`405 Lexington Avenue
`New York, NY 10174
`Tel.: (212) 885-5000
`Attorneys for Petitioners
`Glenmark Pharmaceuticals Ltd.,
`Glenmark Generics Ltd.
`Glenmark Generics Inc., USA
`
`5
`
`

`

`Case: 15-2066 Document: 139 Page: 9 Filed: 08/09/2017
`
`
`
`CERTIFICATE OF INTEREST
`Counsel for Petitioner Hospira, Inc. certifies the following:
`
`1.
`
`The full name of every party or amicus represented by me is:
`
`Hospira, Inc.
`
`2.
`
`The name of the real party in interest represented by me is:
`
`N/A
`
`All parent corporations and any publicly held companies that own 10
`3.
`percent or more of the stock of the party or amicus curiae represented by me are:
`
`Hospira, Inc. is an indirect, wholly-owned subsidiary of Pfizer Inc.
`
`The names of the law firms and the partners or associates that appeared
`4.
`for the party or amicus now represented by me in the trial court or agency or are
`expected to appear in this court are:
`
`Willkie Farr & Gallagher LLP – Thomas J. Meloro and Michael W. Johnson
`
`Proctor Heymen Enerio LLP: Dominick T. Gattuso
`
`Dated: August 9, 2017
`
`
`
`
`
`By: /s/Thomas J. Meloro
`Thomas J. Meloro
`Michael W. Johnson
`Willkie Farr & Gallagher LLP
`787 Seventh Avenue
`New York, NY 10019
`Tel.: (212) 728-8000
`Attorneys for Petitioner
`Hospira, Inc.
`
`6
`
`

`

`Case: 15-2066 Document: 139 Page: 10 Filed: 08/09/2017
`
`
`
`CERTIFICATE OF INTEREST
`Counsel for Petitioners Mylan Laboratories Limited and Agila Specialties Inc.
`
`certifies the following:
`
`
`
`
`
`
`
`
`
`1.
`
`The full name of every party or amicus represented by me is:
`
`Mylan Laboratories Limited and Agila Specialties Inc.
`
`2.
`
`The name of the real party in interest represented by me is:
`
`N/A
`
`All parent corporations and any publicly held companies that own 10
`3.
`
`percent or more of the stock of the party or amicus curiae represented by me are:
`
`Mylan Laboratories Limited and Agila Specialties Inc. are wholly owned sub-
`sidiaries of Mylan Inc., which is indirectly wholly owned by Mylan N.V., a
`publicly held company. No publicly held company owns 10% or more of
`Mylan N.V.’s stock.
`
`The names of the law firms and the partners or associates that appeared
`4.
`
`for the party or amicus now represented by me in the trial court or agency or are
`expected to appear in this court are:
`
`Wilson Sonsini Goodrich & Rosati P.C. – Tung-On Kong and Elham F. Stei-
`ner; Potter Anderson & Corroon – Richard L. Horwitz; David E. Moore, and
`Bindu A. Palapura.
`
`Dated: August 9, 2017
`
`By: /s/ Elham F. Steiner
`Elham F. Steiner
`WILSON SONSINI GOODRICH & ROSATI P.C.
`12235 El Camino Real, Suite 200
`San Diego, CA 92130
`Tel.: (858) 350-2300
`esteiner@wsgr.com
`Attorneys for Petitioners
`Mylan Laboratories Limited and
`Agila Specialties Inc.
`
`7
`
`

`

`Case: 15-2066 Document: 139 Page: 11 Filed: 08/09/2017
`
`
`
`CERTIFICATE OF INTEREST
`Counsel for Petitioner Sandoz Inc. certifies the following:
`
`1.
`
`The full name of every party or amicus represented by me is:
`
`Sandoz Inc.
`
`2.
`
`The name of the real party in interest represented by me is:
`
`N/A
`
`All parent corporations and any publicly held companies that own 10
`3.
`percent or more of the stock of the party or amicus curiae represented by me are:
`
`Novartis AG is the ultimate parent company and owns 100% of Sandoz Inc.
`
`The names of the law firms and the partners or associates that appeared
`4.
`for the party or amicus now represented by me in the trial court or agency or are
`expected to appear in this court are:
`
`Winston & Strawn LLP—George C. Lombardi, Maureen L. Rurka, Kathleen
`B. Barry, Steffen N. Johnson, and Andrew C. Nichols. The following attorneys, who
`represented Sandoz in the trial court, are no longer with Winston & Strawn LLP:
`James F. Hurst, Raymond C. Perkins, John K. Hsu, Mary T. McCarthy, and Michelle
`Munoz Durk.
`
`Phillips Goldman, McLaughlin & Hall (formerly Phillips Goldman &
`Spence)—John C. Phillips Jr. and Megan C. Haney.
`
`.
`Dated: August 9, 2017
`
`
`
`
`
`By: /s/Steffen N. Johnson
`Steffen N. Johnson
`Winston & Strawn LLP
`1700 K Street, N.W.
`Washington, DC 20006
`Tel.: (202) 282-5879
`Attorneys for Petitioner
`Sandoz Inc.
`
`8
`
`

`

`Case: 15-2066 Document: 139 Page: 12 Filed: 08/09/2017
`
`
`
`CERTIFICATE OF INTEREST
`Counsel for Petitioners Sun Pharmaceutical Industries Limited and Sun
`Pharma Global FZE certifies the following:
`
`1.
`
`The full name of every party or amicus represented by me is:
`
`Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE
`
`2.
`
`The name of the real party in interest represented by me is:
`
`Sun Pharmaceutical Industries Limited and Sun Pharma Global FZE
`
`All parent corporations and any publicly held companies that own 10
`3.
`percent or more of the stock of the party or amicus curiae represented by me are:
`
`No publicly held entity holds 10% or more stock in either Sun party named.
`Sun Pharma Global FZE is wholly owned by Sun Pharma Industries Limited.
`
`The names of the law firms and the partners or associates that appeared
`4.
`for the party or amicus now represented by me in the trial court or agency or are
`expected to appear in this court are:
`
`Kelly Farnan and Lori Brewington of Richards, Layton & Finger PA (Wil-
`mington, DE)
`
`B. Jefferson Boggs of Merchant & Gould (Alexandria, VA)
`
`Christopher Sorenson, Rachel Hughey, and Aaron Johnson of Merchant &
`Gould (Minneapolis, MN)
`
`
`
`
`
`
`
`9
`
`

`

`Case: 15-2066 Document: 139 Page: 13 Filed: 08/09/2017
`
`
`
`Dated: August 9, 2017
`
`By: /s/Rachel C. Hughey
`Christopher J. Sorenson
`Rachel C. Hughey
`Aaron M. Johnson
`Merchant & Gould
`IDS Center 3200
`80 South Street
`Minneapolis, MN 55402
`Tel.: (612) 332-5300
`Attorneys for Petitioners
`Sun Pharmaceutical Industries Limited and
`Sun Pharma Global FZE
`
`10
`
`

`

`Case: 15-2066 Document: 139 Page: 14 Filed: 08/09/2017
`
`
`
`CERTIFICATE OF INTEREST
`
`Counsel for Petitioners Wockhardt Bio AG and Wockhardt USA LLC certi-
`fies the following:
`
`1.
`
`The full name of every party or amicus represented by us is:
`
`Wockhardt Bio AG and Wockhardt USA LLC
`
`2.
`
`The names of the real party in interest represented by us is:
`
`Not applicable
`
`All parent corporations and any publicly held companies that own 10
`3.
`percent or more of the stock of the party or amicus curiae represented by me are:
`
`Wockhardt Ltd.
`
`The names of all law firms and the partners or associates that appeared
`4.
`for the party or amicus now represented by me in the trial court or agency or are
`expected to appear in this court are:
`
`DUANE MORRIS LLP: Frederick R. Ball; Patrick C. Gallagher; Richard W. Ri-
`ley. The following attorney, who represented Wockhardt in the trial court, is no
`longer with Duane Morris LLP: Kevin M. Nelson
`
`
`
`
`
`By: /s/ Patrick C. Gallagher
`PATRICK C. GALLAGHER
`DUANE MORRIS LLP
`190 South LaSalle Street
`Chicago, Illinois 60603
`(312) 499-6700
`Attorney for Petitioners Wockhardt Bio AG
`and Wockhardt USA LLC
`
`
`
`Dated: August 9, 2017
`
`
`
`11
`
`

`

`Case: 15-2066 Document: 139 Page: 15 Filed: 08/09/2017
`
`
`
`UNOPPOSED MOTION FOR EXTENSION OF TIME
`TO PETITION FOR REHEARING
`
`Defendants-Appellees Sandoz Inc., Accord Healthcare Inc., Actavis LLC,
`
`Mylan Laboratories Limited, Agila Specialties Inc., Dr. Reddy’s Laboratories, Ltd., Dr.
`
`Reddy’s Laboratories, Inc., Glenmark Pharmaceuticals Ltd., Glenmark Generics Ltd.,
`
`Glenmark Generics Inc., USA, Hospira, Inc., Sun Pharmaceutical Industries, Limited,
`
`Sun Pharma Global FZE, Wockhardt Bio AG and Wockhardt USA LLC’s (collec-
`
`tively, “Petitioners”) respectfully move under Circuit Rule 26(b) for a 30-day exten-
`
`sion, from August 16, 2017, to and including September 15, 2017, to petition for en
`
`banc rehearing. This is our first request. Plaintiff-Appellant Millennium does not
`
`oppose the extension.
`
`In support of this motion, Petitioners advise the Court as follows:
`
`1.
`
`On July 17, 2017, this Court issued an opinion and judgment in this
`
`matter, reversing the district court.
`
`2.
`
`Petitioners are working diligently to complete their petition, but be-
`
`cause of the multiplicity of parties, other court deadlines, and August travel sched-
`
`ules, it will not be possible to complete it by August 16.
`
`3.
`
`The attached declaration of Andrew C. Nichols sets forth good cause
`
`for the requested extension.
`
`
`
`12
`
`

`

`Case: 15-2066 Document: 139 Page: 16 Filed: 08/09/2017
`
`
`
`4.
`
`For example, Andrew C. Nichols and Steffen N. Johnson, counsel for
`
`Sandoz Inc., in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., No. 16-
`
`1284 (Fed. Cir.), have an opposition to a petition for rehearing due August 25.
`
`5.
`
`Additionally, Steffen N. Johnson has the following conflicts: in United
`
`States v. David Ming Pon, No. 17-11455 (11th Cir.), an appellant’s brief due August
`
`21; in BMG Rights Management (US) LLC, et al v. Cox Communications, Inc. et al.,
`
`Nos. 16-1972, 17-1352 & 17-1353 (4th Cir.), a court-ordered supplemental brief due
`
`August 28; and in Leadfactors, LLC v. Cisco Systems, Inc., No. H043081 (Cal. Ct.
`
`App.), an appellant’s brief due September 5.
`
`6.
`
`Counsel for Millennium has no objection to the requested extension.
`
`GEORGE C. LOMBARDI
`MAUREEN L. RURKA
`KATHLEEN B. BARRY
`WINSTON & STRAWN LLP
`35 W. Wacker Drive
`Chicago, IL 60601
`(312) 558-5600
`
`
`
`
`
`Respectfully submitted,
`
`/s/ Steffen N. Johnson
`STEFFEN N. JOHNSON
`ANDREW C. NICHOLS
`WINSTON & STRAWN LLP
`1700 K Street, N.W.
`Washington, DC 20005
`(202) 282-5000
`
`
`
`
`
`Counsel for Petitioner Sandoz Inc.
`
`13
`
`
`
`
`
`
`
`
`
`

`

`Case: 15-2066 Document: 139 Page: 17 Filed: 08/09/2017
`
`ROBYN AST-GMOSER
`Polsinelli PC
`100 S. Fourth Street, Suite 1000
`St. Louis, MO 63102
`(314) 622-6614
`Counsel for Petitioner
`Actavis LLC
`
`
`TUNG-ON KONG
`WILSON SONSINI GOODRICH
`& ROSATI P.C.
`One Market Street
`Spear Tower, Suite 3600
`San Francisco, CA 94105
`(415) 947-2000
`Counsel for Petitioners
`Mylan Laboratories Limited and
`Agila Specialties Inc.
`
`ELHAM F. STEINER
`WILSON, SONSINI, GOODRICH
`& ROSATI, PC
`12235 El Camino Real, Suite 200
`San Diego, CA 92130
`(858) 350-2300
`Counsel for Petitioners
`Mylan Laboratories Limited
`and Agila Specialties Inc.
`
`
`PAUL A. BRAIER
`P. BRANKO PEJIC
`GREENBLUM & BERNSTEIN, P.L.C.
`1950 Roland Clarke Place
`Reston, VA 20191
`(703) 716-1191
`Counsel for Petitioner
`Accord Healthcare Inc.
`
`STUART D. SENDER
`LOUIS H. WEINSTEIN
`ELLEN T. LOWENTHAL
`BUDD LARNER, P.C.
`150 John F. Kennedy Parkway
`Short Hills, NJ 07078
`(973) 379-4800
`Counsel for Petitioners
`Dr. Reddy’s Laboratories, Ltd. and
`Dr. Reddy’s Laboratories, Inc.
`
`CHRISTOPHER J. SORENSON
`RACHEL C. HUGHEY
`AARON M. JOHNSON
`MERCHANT & GOULD
`IDS Center 3200
`80 South Street
`Minneapolis, MN 55402
`(612) 332-5300
`Counsel for Petitioners
`Sun Pharmaceutical Industries
`Limited and Sun Pharma Global FZE
`
`
`14
`
`
`
`
`
`

`

`Case: 15-2066 Document: 139 Page: 18 Filed: 08/09/2017
`
`JAY P. LESSLER
`PAUL M. ZAGAR
`BLANK ROME LLP
`405 Lexington Avenue
`New York, NY 10174
`(212) 885-5176
`Counsel for Petitioners
`Glenmark Pharmaceuticals Ltd.,
`Glenmark Generics Ltd., and
`Glenmark Generics Inc., USA
`
`PATRICK GALLAGHER
`DUANE MORRIS LLP
`190 South LaSalle Street
`Chicago, IL 60603
`(312) 499-6700
`Counsel for Petitioners
`Wockhardt Bio AG and
`Wockhardt USA LLC
`
`AUGUST 9, 2017
`
`
`
`
`
`
`
`THOMAS J. MELORO
`MICHAEL W. JOHNSON
`WILLKIE FARR & GALLAGHER LLP
`787 Seventh Avenue
`New York, NY 10019
`(212) 728-8000
`Counsel for Petitioner Hospira, Inc.
`
`
`
`
`
`
`
`15
`
`

`

`
`
`
`
`
`
`Case: 15-2066 Document: 139 Page: 19 Filed: 08/09/2017
`
`DECLARATION OF ANDREW C. NICHOLS IN SUPPORT OF
`UNOPPOSED MOTION FOR EXTENSION OF TIME
`TO PETITION FOR REHEARING
`
`Pursuant to 28 U.S.C. §1746, Andrew C. Nichols as follows:
`
`1.
`
`I am an attorney representing Sandoz in this matter. Our petition for
`
`rehearing—which will be joined by multiple Defendant-Appellees, all listed on the
`
`cover of the underlying motion—is due to be filed on August 16, 2017.
`
`2.
`
`3.
`
`This is our first request for an extension of time to seek rehearing.
`
`On July 17, 2017, this Court issued an opinion and judgment in this
`
`matter, reversing the district court.
`
`4.
`
`Petitioners are working diligently to complete their petition, but be-
`
`cause of the multiplicity of parties, other court deadlines, and August travel sched-
`
`ules, it will not be possible to complete it by August 16.
`
`5.
`
`For example, concerning other deadlines, in Helsinn Healthcare S.A. v.
`
`Teva Pharmaceuticals USA, Inc., No. 16-1284 (Fed. Cir.), a case regarding the scope
`
`of the on-sale bar under the America Invents Act, Andrew C. Nichols and Steffen N.
`
`Johnson have an opposition to a petition for rehearing due August 25.
`
`6.
`
`Additionally, Steffen N. Johnson has the following conflicts: in United
`
`States v. David Ming Pon, No. 17-11455 (11th Cir.), a direct appeal from a convic-
`
`tion of 20 counts of fraud and forfeiture and restitution of $14 million, an appellant’s
`
`1
`
`

`

`Case: 15-2066 Document: 139 Page: 20 Filed: 08/09/2017
`
`
`
`brief due August 21; in BMG Rights Management (US) LLC v. Cox Communica-
`
`tions, Inc. et al., Nos. 16-1972, 17-1352 & 17-1353 (4th Cir.), an appeal from an
`
`order awarding $25 million in damages and an award of attorneys’ fees, a court-
`
`ordered supplemental brief due August 28; and in Leadfactors, LLC v. Cisco Sys-
`
`tems, Inc., No. H043081 (Cal. Ct. App.), an appeal from a trial court’s denial of over
`
`$2 million in attorneys’ fees, an appellant’s brief due September 5.
`
`7.
`
`An extension of 30 days, to and including September 15, 2017, should
`
`be sufficient to permit Petitioners to address the Court’s opinion.
`
`8.
`
`Counsel for Millennium has no objection to the requested extension.
`
`I declare under penalty of perjury that the foregoing is true and correct.
`
`Executed on August 9, 2017.
`
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Andrew C. Nichols
`
`
`
`
`
`2
`
`

`

`Case: 15-2066 Document: 139 Page: 21 Filed: 08/09/2017
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on August 9, 2017, I caused the foregoing to be electron-
`
`ically filed with the Clerk of Court using the CM/ECF system, and thereby served
`
`/s/ Andrew C. Nichols
`ANDREW C. NICHOLS
`
`Counsel for Petitioner Sandoz Inc.
`
`
`
`on counsel for Defendant-Appellant.
`
`Dated: August 9, 2017
`
`
`
`
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.